FORA Capital’s Soleno Therapeutics SLNO Stock Holding History

FORA Capital’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,964	Closed	-$601K	–	536
2026 Q1	$601K	Buy	17,964 +985	+6%	+$38.6K	0.04%	288
2025 Q4	$786K	Buy	+16,979	New	+$931K	0.1%	242
2025 Q3	–	Sell	-3,312	Closed	-$277K	–	655
2025 Q2	$277K	Sell	3,312 -946	-22%	-$70.8K	0.03%	413
2025 Q1	$304K	Buy	+4,258	New	+$207K	0.03%	397

FORA Capital's SLNO Position: Q2 2026 in Review

FORA Capital sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 17,964 shares — an estimated $601K sold.

FORA Capital first reported a position in SLNO in Q1 2025 and held it in 4 quarters. The position peaked at $786K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

FORA Capital reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
FORA Capital sold 17,964 Soleno Therapeutics shares in Q2 2026, an estimated $601K.
FORA Capital first reported a position in Soleno Therapeutics in Q1 2025 and held it in 4 quarters.
FORA Capital's Soleno Therapeutics position peaked at $786K in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.